<DOC>
	<DOC>NCT02308098</DOC>
	<brief_summary>The purpose of this study is to confirm equivalent bronchodilator efficacy of the test product compared to the reference product.</brief_summary>
	<brief_title>To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product</brief_title>
	<detailed_description />
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<criteria>Main inclusion criteria: Written informed consent Asthma diagnosis for at least 6 months Prebronchodilator FEV1 4590% of the predicted value Demonstration of reversible airway obstruction Stable asthma on the same regular treatment for at least 4 weeks before the study Nonsmoker for at least 6 months before the study Main exclusion criteria Respiratory infection within 4 weeks before the study Smoking history of more than 10 packyears Other severe chronic respiratory disease than asthma Concurrent illness that would interfere with the interpretation of the study results or constitute a health risk for the patient if he/she takes part in the study Corrected QT interval &gt; 450 ms in males or &gt; 470 ms in females Abnormal serum potassium value or other clinically significant laboratory finding Systolic blood pressure over 180 mmHg and/or diastolic blood pressure over 100 mmHg Treatment with a longacting β2agonist, a xanthinederivative, a βblocker or with a corticosteroid (other than inhaled) within 4 weeks before the study Use of drugs that prolong QTinterval Women who are pregnant, breastfeeding or without reliable contraception Participation in another clinical drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>